Sharing is caring!

Thermo Fisher Scientific and Innoforce signs a joint venture agreement. 

Thermo Fisher Scientific and Innoforce recently announced that they have signed a joint venture agreement to establish a new pharmaceutical service facility in China for the development and manufacturing of integrated biologics and sterile drugs.

The new facility site which is expected to be completed by 2022, will incorporate stringent quality control processes that meet or exceed regulatory guidelines established by the China National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA), and other respective authorities.

Both companies are excited about this new collaboration as they seek to bring innovative therapies to the world.

(Source: BioPharma Reporter, 2020)

AC Immune and WuXi Biologics Enters Into A Strategic Partnership.

AC Immune and WuXi Biologics recently announced plans to accelerate the development of AC Immune’s TDP-43 antibody into clinical development for NeuroOrphan indications.

The strategic partnership will leverage AC Immune’s proprietary drug discovery and development platforms and WuXi Biologics’ expertise in manufacturing innovative biologics whilst focusing on developing AC Immune’s clinical antibody candidate to ensure it has a high-affinity for TDP-43 and is capable of preventing the intercellular spread of toxic species.

Under the terms of the agreement, AC Immune will gain access to WuXi Biologics’ proprietary platforms including the cell line development platform, for the clinical manufacturing of AC Immune’s TDP-43 monoclonal antibodies while retaining all intellectual property rights.

(Source: Global News Wire, 2020)

Eli Lilly’s Monoclonal Antibody Approved To Be Used For Treatment Of COVID-19.

Eli Lilly’s Monoclonal Antibody, LY-CoV555 (bamlanivimab) has recently received “Emergency Use Authorization” from the US Food and Drug Administration (FDA) to treat patients with mild to moderate COVID-19.

LY-CoV555 is a neutralizing lgG1 monoclonal antibody that targets the spike protein of SARS-CoV-2 and prevents viral attachment and entry to the human cells.

The US government will be allocating 300,000 doses of LY-CoV555 to high-risk patients for free.

LY-CoV555 remains an investigational drug and has not been approved under a Biologics License Application (BLA) although it was granted for emergency use to help diagnose, treat, or prevent COVID-19.

Eli Lilly expects to manufacture up to 1 million doses of LY-CoV555 by the end of 2020.

(Source: Biopharma Reporter, 2020)